The populations of patients being treated for ESRD and dialysis patients in Iran have increased to over 57000 until 2017 and of these patients, 29200 were undergoing hemodialysis (HD) treatment, 1624 were undergoing peritoneal dialysis (PD) treatment and around 27000 people were living with kidney transplants. In Iran, ESRD population growth rate is annually in range of 4-5% and population rate is 1.2%. This comparison suggests that economic factors may impose restrictions on treatment and it is considered as a medical challenge for the country.
The prevalence of treated ESRD patients in the general population shows a high global variation, ranging from under 100 to over 2,000 patients per million population (p.m.p.). ESRD prevalence is highest in Taiwan with around 3,400 p.m.p., followed by Japan with around 2,720 p.m.p. and then the USA with around 2,180 p.m.p. It averages about 1,160 p.m.p. in the 28 countries that make up the European Union (EU). The much lower global average of 510 p.m.p. suggests that, from the global perspective, access to treatment is still limited in many countries and a number of patients with terminal renal failure do not receive treatment. Increasing global prevalence values over the years indicate a general increase in the numbers of people requiring care for ESRD as well as a gradual improvement in the access to the treatment. ESRD prevalence in Iran is 680 p.m.p. and it higher than global average.
Exhibitor Data Sheet